Regeneron Study Site

Raleigh, North Carolina

We've found

1 trials

at this facility

Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)

Status: Enrolling, Phase I
Updated: 1/4/2016

from

Raleigh, NC

Use our guide to learn which trials are right for you!